ms zentrum bamberg
Industry / private company
Location:
Bamberg,
Germany (DE)
Anti-SARS-CoV-2 vaccination immune response in MS patients: interim results of a multicentre, prospective cohort study (2022)
Berthele A, Goedel C, Kallmann B, Kowarik M, Lehmann-Horn K, Marziniak M, Meyer C, et al.
Conference contribution
Alemtuzumab as rescue therapy in a cohort of 50 relapsing-remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study (2018)
Huhn K, Bayas A, Doerck S, Frank B, Gerbershagen K, Hellwig K, Kallmann B, et al.
Journal article
"Time is brain" in relapsing remitting multiple sclerosis : Current treatment concepts in immunotherapy (2015)
Linker R, Kallmann BA, Kleinschnitz C, Rieckmann P, Maeurer M, Schwab S
Journal article